A. B. Zelentsova
A. B. Zelentsova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Inna Ivanovna Terninko
Saint Petersburg State Chemical and Pharmaceutical University (SPCPU)
3 shared publications - Dmitriy Yur'Evich Ivkin
Center of Experimental Pharmacology, St. Petersburg State Chemical Pharmaceutical University, 14 Prof. Popov Str., 197022 Saint-Petersburg, Russia
2 shared publications - Yuliya Eduardovna Generalova
ITMO University; Saint-Petersburg State Chemical and Pharmaceutical University
2 shared publications - A. P. Procyuk
Saint-Petersburg State Chemical and Pharmaceutical University
1 shared publication - A. Yu. Grishina
Saint Petersburg State Chemical and Pharmaceutical University (SPCPU)
1 shared publication - Andrei A. Karpov
Almazov National Medical Research Centre
1 shared publication
Latest Publications
- 22 May 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Development, validation and testing of the HPLC-UV bioanalytical method for quantification of etmaben in blood plasma and organs of rats
Introduction. Currently, the search and development of innovative cardiotropic drugs is an urgent task for pharmaceutical science. One such drug is a derivative of malonic acid, etmaben, which was synthesized at the St. Petersburg State Chemical and Pharmaceutical University (SPCPU). To conduct preclinical and clinical studies, it is necessary to develop and validate a bioanalytical method that allows for the quantitative determination of etmaben in complex biological matrices with minimal time and resource requirements. Aim. The aim of the study is to develop and validate a method for the determination of etmaben in the blood plasma and organs of laboratory animals using high-performance liquid chromatography with ultraviolet detection (HPLC-UV) followed by testing and obtaining a pool of data on the distribution of etmaben in the organs and tissues of experimental animals. Materials and methods. The development and validation of the bioanalytical method, as well as the quantitative determination of etmaben, were performed on a Flexar liquid chromatograph (PerkinElmer, USA) equipped with a UV detector and a thermostatted autosampler, using a Kromasil 100, 150 × 2.1, C8, 3.5 μm column (AkzoNobel, Netherlands). Detection was performed at a wavelength of 270 nm. A pharmacological experiment to test the method was conducted on 20 outbred male rats (Kurchatov Institute – "Rappolovo", Russia), divided into a control group (intact animals, n = 10) and a group with experimental chronic heart failure (CHF) ( n = 10), a model of which was induced by ligation of the left coronary artery. All animals received etmaben intragastrically at a dose of 60 mg/kg for 30 days. Whole blood samples were collected for analysis on day 30, and organs (heart and kidneys) were isolated. Etmaben was quantified in plasma and tissue homogenates using HPLC-UV after sample preparation, including protein precipitation with acetonitrile (HPLC Grade, cat. no. A/0627/17, Thermo Fisher Scientific, USA). Results and discussion. Optimal conditions for the chromatographic determination of etmaben in biological matrices (blood plasma and tissue homogenates) using HPLC-UV were developed. The developed method was validated using the following validation parameters: selectivity, calibration curve, accuracy, precision, lower limit of quantification (LLOQ), carryover effect, no effect of sample dilution and stability. The degree of etmaben recovery from the matrix was also assessed. The LLOQ for etmaben was 5.0 ng/mL. The developed method was successfully applied to assess etmaben distribution in the organs and tissues of laboratory animals at specific stages of preclinical testing. In CHF, plasma concentrations of etmaben doubled, and in pathologically altered myocardium, they increased by 47 % compared to control animals. Conclusion. A bioanalytical method for determining etmaben using HPLC-UV was developed and validated. It was tested during preclinical trials to study the drug's distribution in organs and tissues of experimental animals. The observed selective accumulation of etmaben in damaged myocardium confirms its therapeutic relevance for the treatment of CHF.
- 22 May 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Development, validation and testing of the HPLC-UV bioanalytical method for quantification of etmaben in blood plasma and organs of rats
Introduction. Currently, the search and development of innovative cardiotropic drugs is an urgent task for pharmaceutical science. One such drug is a derivative of malonic acid, etmaben, which was synthesized at the St. Petersburg State Chemical and Pharmaceutical University (SPCPU). To conduct preclinical and clinical studies, it is necessary to develop and validate a bioanalytical method that allows for the quantitative determination of etmaben in complex biological matrices with minimal time and resource requirements. Aim. The aim of the study is to develop and validate a method for the determination of etmaben in the blood plasma and organs of laboratory animals using high-performance liquid chromatography with ultraviolet detection (HPLC-UV) followed by testing and obtaining a pool of data on the distribution of etmaben in the organs and tissues of experimental animals. Materials and methods. The development and validation of the bioanalytical method, as well as the quantitative determination of etmaben, were performed on a Flexar liquid chromatograph (PerkinElmer, USA) equipped with a UV detector and a thermostatted autosampler, using a Kromasil 100, 150 × 2.1, C8, 3.5 μm column (AkzoNobel, Netherlands). Detection was performed at a wavelength of 270 nm. A pharmacological experiment to test the method was conducted on 20 outbred male rats (Kurchatov Institute – "Rappolovo", Russia), divided into a control group (intact animals, n = 10) and a group with experimental chronic heart failure (CHF) ( n = 10), a model of which was induced by ligation of the left coronary artery. All animals received etmaben intragastrically at a dose of 60 mg/kg for 30 days. Whole blood samples were collected for analysis on day 30, and organs (heart and kidneys) were isolated. Etmaben was quantified in plasma and tissue homogenates using HPLC-UV after sample preparation, including protein precipitation with acetonitrile (HPLC Grade, cat. no. A/0627/17, Thermo Fisher Scientific, USA). Results and discussion. Optimal conditions for the chromatographic determination of etmaben in biological matrices (blood plasma and tissue homogenates) using HPLC-UV were developed. The developed method was validated using the following validation parameters: selectivity, calibration curve, accuracy, precision, lower limit of quantification (LLOQ), carryover effect, no effect of sample dilution and stability. The degree of etmaben recovery from the matrix was also assessed. The LLOQ for etmaben was 5.0 ng/mL. The developed method was successfully applied to assess etmaben distribution in the organs and tissues of laboratory animals at specific stages of preclinical testing. In CHF, plasma concentrations of etmaben doubled, and in pathologically altered myocardium, they increased by 47 % compared to control animals. Conclusion. A bioanalytical method for determining etmaben using HPLC-UV was developed and validated. It was tested during preclinical trials to study the drug's distribution in organs and tissues of experimental animals. The observed selective accumulation of etmaben in damaged myocardium confirms its therapeutic relevance for the treatment of CHF.
- Open Access
- 26 December 2024
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Comparative efficacy study of experimental chronic heart failure
Introduction. Combination therapy of chronic heart failure (CHF) is an urgent and important treatment strategy, as it allows to achieve an improvement in the prognosis, optimal control of the symptoms of the disease and an increase in the quality of life of patients.Aim. Comparison of the effectiveness of the malonic acid derivative ethmaben, the sodium-glucose cotransporter inhibitor empagliflozin and their combinations with the variability of the starting drug in experimental post-infarction chronic heart failure in rats.Materials and methods. In a model of post-infarction chronic heart failure, reproduced by permanent ligation of the left coronary artery in rats, an echocardiographic study was used to compare etmaben and empagliflozin monotherapy with a combined regimen of these drugs. The concentration of etmaben in the myocardium was assessed by HPLC.Results and discussion. Antagonism between etmaben and empagliflozin was revealed, manifested by a decrease in the effect of combination therapy in relation to any of the components, a decrease in the concentration of malonic acid derivative in the myocardium under the action of a type 2 sodium-glucose cotransporter inhibitor was shown.Conclusion. Based on the data obtained, additional studies of pharmacokinetics and pharmacodynamics of etmaben were planned.
- 26 December 2024
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessComparative efficacy study of experimental chronic heart failure
Introduction. Combination therapy of chronic heart failure (CHF) is an urgent and important treatment strategy, as it allows to achieve an improvement in the prognosis, optimal control of the symptoms of the disease and an increase in the quality of life of patients.Aim. Comparison of the effectiveness of the malonic acid derivative ethmaben, the sodium-glucose cotransporter inhibitor empagliflozin and their combinations with the variability of the starting drug in experimental post-infarction chronic heart failure in rats.Materials and methods. In a model of post-infarction chronic heart failure, reproduced by permanent ligation of the left coronary artery in rats, an echocardiographic study was used to compare etmaben and empagliflozin monotherapy with a combined regimen of these drugs. The concentration of etmaben in the myocardium was assessed by HPLC.Results and discussion. Antagonism between etmaben and empagliflozin was revealed, manifested by a decrease in the effect of combination therapy in relation to any of the components, a decrease in the concentration of malonic acid derivative in the myocardium under the action of a type 2 sodium-glucose cotransporter inhibitor was shown.Conclusion. Based on the data obtained, additional studies of pharmacokinetics and pharmacodynamics of etmaben were planned.
- Open Access
- 10 November 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
End-to-end Standardization of Original Medicines when Determining Related Impurities
Introduction. For tablets “Malоben, 60 mg” and “Etmaben, 300 mg”, permission was received to conduct phase I clinical trials, so they required a full cycle of research and standardization.Aim. Development of a unified analytical procedure for the determination of related impurities in samples (RS, API, FPP) of Malоben and Ethmaben.Materials and methods. RSs were obtained at the Department of Organic Chemistry of the St. Petersburg State Chemical and Pharmaceutical University; the synthesis of APIs and the production of FPP were carried out on an industrial scale in pharmaceutical production. The studies were carried out on a Flexar liquid chromatograph (PerkinElmer, USA), equipped with a pump (formation of a gradient on the low-pressure side), an autosampler, a column thermostat, a UV detector and a chromatographic column Intersil® ODS-3V, 5 µm, 100 Å, 250 × 4, 6 (Phenomenex, Japan).Results and discussion. In the research, uniform optimal chromatographic conditions were selected using the HPLC method to determine the RP in RS, API and FPP of Maloben and Ethmaben. Column C18 250×4.6 mm, mobile phase 0.1% phosphoric acid and acetonitrile (gradient elution), flow rate 1 ml/min, sample volume 10 µl, UV detector (270 nm). They were validated in terms of specificity, linearity, detection limit, precision, robustness, and solution stability. Analytical concentration levels were selected for the formation of draft regulatory documents. Using the developed analytical technique, samples of RS, API and tablets of malоben and ethmaben were analyzed.Conclusion. A full cycle of research was carried out, an analytical methodology was developed and related impurities were identified in RS, API and FPP of Maloben and Ethmaben.
- 10 November 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessEnd-to-end Standardization of Original Medicines when Determining Related Impurities
Introduction. For tablets “Malоben, 60 mg” and “Etmaben, 300 mg”, permission was received to conduct phase I clinical trials, so they required a full cycle of research and standardization.Aim. Development of a unified analytical procedure for the determination of related impurities in samples (RS, API, FPP) of Malоben and Ethmaben.Materials and methods. RSs were obtained at the Department of Organic Chemistry of the St. Petersburg State Chemical and Pharmaceutical University; the synthesis of APIs and the production of FPP were carried out on an industrial scale in pharmaceutical production. The studies were carried out on a Flexar liquid chromatograph (PerkinElmer, USA), equipped with a pump (formation of a gradient on the low-pressure side), an autosampler, a column thermostat, a UV detector and a chromatographic column Intersil® ODS-3V, 5 µm, 100 Å, 250 × 4, 6 (Phenomenex, Japan).Results and discussion. In the research, uniform optimal chromatographic conditions were selected using the HPLC method to determine the RP in RS, API and FPP of Maloben and Ethmaben. Column C18 250×4.6 mm, mobile phase 0.1% phosphoric acid and acetonitrile (gradient elution), flow rate 1 ml/min, sample volume 10 µl, UV detector (270 nm). They were validated in terms of specificity, linearity, detection limit, precision, robustness, and solution stability. Analytical concentration levels were selected for the formation of draft regulatory documents. Using the developed analytical technique, samples of RS, API and tablets of malоben and ethmaben were analyzed.Conclusion. A full cycle of research was carried out, an analytical methodology was developed and related impurities were identified in RS, API and FPP of Maloben and Ethmaben.
- Open Access
- 27 October 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Development of Technology of Phytosubstantiation of Silybum marianum L. Fruits as a Component of Complex Therapy of Liver Diseases
Разработка технологии получения фитосубстанции расторопши пятнистой плодов ( Silybum marianum L.) в качестве компонента комплексной терапии заболеваний печени
- 27 October 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessDevelopment of Technology of Phytosubstantiation of Silybum marianum L. Fruits as a Component of Complex Therapy of Liver Diseases
Разработка технологии получения фитосубстанции расторопши пятнистой плодов ( Silybum marianum L.) в качестве компонента комплексной терапии заболеваний печени